Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results for its gast...

Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets

In a report released today, from Jefferies maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $225.00. In addition to Jefferie...

Jefferies Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

All of the top stock market stories are ready to go in the TipRanks daily wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Jazz Pharmaceuticals stock gained on Monday after the company posted positive clinical trial data.


Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results

Jazz Pharmaceuticals ( ($JAZZ) ) has issued an announcement. On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3...

Jazz Pharmaceuticals Announces Positive Phase 3 Trial Results

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $230.00. The ...

Bank of America Securities Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

In a report released on November 10, Leonid Timashev from RBC Capital maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $155....

Market Cap	$10.97B	P/E Ratio	42.43
52W High	$182.99	52W Low	$95.49
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	53.8%	52W Position	93.1%
Overall Score	60	Value Score	40
Quality Score	--	Technical Score	81

EPS Current Est	$4.17	EPS Next Est	$19.19
EPS Growth Est	+360.2%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JAZZ	$176.93	+0.68%	1.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JAZZ	$176.93	+0.7%	1.01M
3
4
5
6

JAZZ

JAZZ

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Jazz Pharmaceuticals plc Data in Excel

Get Jazz Pharmaceuticals plc Data in Excel